加载中
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
前收盘价
US$16.64
+US$0.27 · +1.65%
盘前
US$16.64
US$0.00 · 0.00%
10月12日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
35
偏贵
情绪
47
多空交织
风险
44
风险偏高
动量
66
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
日内区间
当前US$16.64
52周区间
当前US$16.64
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$35.20
上涨空间 111.54%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
